Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solriamfetol in OSA with cognitive impairment
NCT04789174Phase 4Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- May 2021
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 4 trial of solriamfetol in Excessive Daytime Sleepiness (EDS), sponsored by Axsome Therapeutics, Inc.. Started May 2021; status: completed.
02
Drugs
solriamfetol
03
Conditions
Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on NCT04789174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789174.